ClinicalTrials.gg
Not yet recruitingNCT06280430Updated Feb 28, 2024

Vascular Affection in Behcet Disease

An observational study in Behcet Disease and Vascular Involvement, sponsored by Assiut University. Not yet recruiting. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Assiut University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
90
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Behcet Syndrome by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · Assiut University.

Planned enrollment
Largest of 14
90 · median 77
Started
2024
with 5 others
Observational
14 of 18
6 open now
Registered
12th of 18
by date

Among the 18 studies in Behcet Syndrome by Assiut University, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2024, is one of 14 observational ones, and was the 12th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

6 of the 18 studies in Behcet Syndrome by Assiut University are open now. Recruiting first, the newest first:

All 6 open studies →

Where they have run

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Behcet Syndrome by Assiut University, or all of them as a file.
02

Study summary

To measure the level of serum elafin in patients with behcet disease and to assess the correlation between serum elafin and vascular affection and their relation with disease activity

Read the detailed description

Behcet disease is a chronic multi systemic inflammatory disease characterized by recurrent oral and genital ulcers and multiple systemic affection . Elafin is a serine protease inhibitor produced mainly by epithelial cells . previous studies documented the role of serum elafin in pathogenesis of behcet disease.vascular complications may be one if the earliest manifestation leading to the diagnosis of behcet disease.

03

Conditions studied

  • Behcet Disease and Vascular Involvement

Browse trials for

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

45 patients with behcet disease aged(20-45) in comparison with 45 heathy participant s

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients diagnosed as behcet disease Age (20-45)

Exclusion criteria

Exclusion Criteria:

  • age \<20 and >45 Other diseases Risk factors (ischemic heart disease, diabetes) Chronic conditions (, chronic kidney disease)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with behcet disease
  • Healthy control group
06

What researchers measure

Primary outcomes

  1. To measure the level of serum elafin in behcet patients and compare it with control group

    Measure the level of serum elafin in behcet and its relation to disease activity and vascular involvement

    Time frame: Within 1year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Mar 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartEst.
Mar 1, 2024
Primary completionEst.
Mar 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06280430
Lead sponsor
Assiut University
Responsible party
Lobna Amer Araby Ahmed (Assuit, Assiut University) — Principal investigator
First posted
Feb 28, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Mar 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Feb 28, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion